Capecitabine (C) and bevacizumab (B) for nonresectable metastatic colorectal cancer (mCRC) patients: Results from phase II AIO 0105 trial.Albrecht Kretzschmar, Dirk Arnold, S. Hegewisch-Becker et al.|Journal of Clinical Oncology|2010Cited by 0
Nal-Iri and 5-FU/LV Compared to 5-FU/LV in Patients with Cholangio- and Gallbladder Carcinoma Previously Treated with Gemcitabine-Based Therapies: The AIO NALIRICC TrialArndt Vogel, Martha M. Kirstein, Anna Saborowski et al.|SSRN Electronic Journal|2024Cited by 0